A share price of Immunovant Inc [IMVT] is currently trading at $37.66, down -1.82%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The IMVT shares have gain 3.18% over the last week, with a monthly amount drifted -4.22%, and not seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
On 12, February 2024, Immunovant Reports Financial Results and Provides Corporate Updates for the Quarter Ended December 31, 2023. In a post published today on Yahoo Finance, Immunovant plans to initiate 4-5 potentially registrational programs for IMVT-1402 over the next fiscal year.
From an analyst’s perspective:
Immunovant Inc [NASDAQ: IMVT] stock has seen the most recent analyst activity on February 20, 2024, when JP Morgan initiated its Overweight rating and assigned the stock a price target of $51. Previously, Wolfe Research started tracking the stock with Outperform rating on February 15, 2024, and set its price target to $55. On December 12, 2023, Deutsche Bank initiated with a Buy rating and assigned a price target of $50 on the stock. UBS upgraded its rating to a Buy and increased its price target to $55 on October 13, 2023. Raymond James upgraded its rating to a Outperform but $40 remained the price target by the analyst firm on September 26, 2023. BofA Securities started tracking with a Buy rating for this stock on May 01, 2023, and assigned it a price target of $26. In a note dated April 25, 2023, Citigroup initiated an Buy rating and provided a target price of $28 on this stock.
Immunovant Inc experienced fluctuations in its stock price throughout the past year between $14.05 and $45.58. Currently, Wall Street analysts expect the stock to reach $5 within the next 12 months. Immunovant Inc [NASDAQ: IMVT] shares were valued at $37.66 at the most recent close of the market. An investor can expect a potential drop of -86.72% based on the average IMVT price forecast.
Analyzing the IMVT fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -0.34, Equity is -0.61 and Total Capital is -0.37. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.0.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 36.96 points at the first support level, and at 36.25 for the second support level. However, for the 1st resistance point, the stock is sitting at 38.29, and for the 2nd resistance point, it is at 38.91.
Immunovant Inc [IMVT] reported earnings per share of -$0.36 for its fiscal quarter that ended on 12/30/2023. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of -$0.43/share, meaning a difference of $0.07 and a surprise factor of 16.30%. By comparison, the stated earnings for the previous quarter ended on 9/29/2023 were -$0.45 per share as compared to estimates of -$0.47 per share, a difference of $0.02 representing a surprise of 4.30%.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Immunovant Inc [NASDAQ:IMVT] is 22.14. Further, the Quick Ratio stands at 22.14, while the Cash Ratio is 21.52.
Transactions by insiders
Recent insider trading involved Salzmann Peter, Chief Executive Officer, that happened on Feb 22 when 13454.0 shares were sold. Chief Financial Officer, Barnett Eva Renee completed a deal on Feb 22 to sell 2930.0 shares. Meanwhile, Chief Medical Officer Macias William L. sold 2221.0 shares on Feb 22.
